iifl-logo-icon 1

Sun Pharma Advanced Research Company Ltd Share Price

223.63
(1.19%)
Jul 22, 2024|10:09:52 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open220.8
  • Day's High223.85
  • 52 Wk High472.8
  • Prev. Close221
  • Day's Low217.3
  • 52 Wk Low196.1
  • Turnover (lac)195.35
  • P/E0
  • Face Value1
  • Book Value3.84
  • EPS0
  • Mkt. Cap (Cr.)7,257.28
  • Div. Yield0
No Records Found

Sun Pharma Advanced Research Company Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

220.8

Prev. Close

221

Turnover(Lac.)

195.35

Day's High

223.85

Day's Low

217.3

52 Week's High

472.8

52 Week's Low

196.1

Book Value

3.84

Face Value

1

Mkt Cap (₹ Cr.)

7,257.28

P/E

0

EPS

0

Divi. Yield

0

Sun Pharma Advanced Research Company Ltd Corporate Action

15 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

12 Jul 2023

12:00 AM

AGM

Announcement Date: 12 Jul, 2023

arrow

Sun Pharma Advanced Research Company Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sun Pharma Advanced Research Company Ltd SHAREHOLDING SNAPSHOT

22 Jul, 2024|10:31 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 65.67%

Foreign: 0.00%

Indian: 65.67%

Non-Promoter- 2.82%

Institutions: 2.82%

Non-Institutions: 31.50%

Custodian: 0.00%

Share Price

Sun Pharma Advanced Research Company Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

32.45

32.45

261.45

26.21

Preference Capital

0

0

0

0

Reserves

92.4

480.32

-230.22

-194.46

Net Worth

124.85

512.77

31.23

-168.25

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

252.95

76.81

78.25

181.02

yoy growth (%)

229.3

-1.84

-56.76

12.24

Raw materials

-18.17

-23.92

-26.8

-25.16

As % of sales

7.18

31.14

34.25

13.89

Employee costs

-91.58

-93.08

-100.92

-84.3

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

-151.13

-312.4

-245.97

-119.03

Depreciation

-10.92

-9.48

-8.18

-8.23

Tax paid

0

0

0

0

Working capital

59.11

-68.31

-89.36

46.78

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

229.3

-1.84

-56.76

12.24

Op profit growth

-56.46

27.78

97.72

94.16

EBIT growth

-54.64

25.98

109.73

72.79

Net profit growth

-51.62

58.58

65.49

70.07

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023

Gross Sales

75.55

238.78

Excise Duty

0

0

Net Sales

75.55

238.78

Other Operating Income

0

0

Other Income

29.47

10.88

Sun Pharma Advanced Research Company Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.65

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,519.8

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.5

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.45

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,636

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Sun Pharma Advanced Research Company Ltd

Management

Register Office

Registrar Office

Director

T Rajamannar

Director

Sudhir V Valia

Independent Director

Bhavna Doshi

Independent Director

Ferzaan Engineer

Independent Director

Robert Spiegel

Chairman (Non-Executive)

Dilip S Shanghvi

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Sun Pharma Advanced Research Company Ltd

Summary

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCEs) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Ltd was incorporated on March 1, 2006 as an innovative and development company. They commenced operations on March 22, 2006. As per Scheme of Arrangement, all assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries Research & Development undertaking stands transferred and vested in the Company with effect from Appointed date on February 28, 2007. The demerger became effective on March 28, 2007. On Scheme being effective, the Company ceased to be subsidiary of Sun Pharmaceutical Industries Ltd., and the demerged Company.During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the Company.During 2011, the Company announced USFDA approval for DOCEFREZ (docetaxel) for Injection. During 2014, the Company announced Govt. of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN).On 1 Decembe
Read More

Company FAQs

What is the Sun Pharma Advanced Research Company Ltd share price today?

Down Arrow

The Sun Pharma Advanced Research Company Ltd shares price on N/A is Rs.₹224.8 today.

What is the Market Cap of Sun Pharma Advanced Research Company Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharma Advanced Research Company Ltd is ₹7295.25 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Sun Pharma Advanced Research Company Ltd?

Down Arrow

The PE and PB ratios of Sun Pharma Advanced Research Company Ltd is 0 and 57.38 as of 22 Jul ‘24

What is the 52 Week High and Low of Sun Pharma Advanced Research Company Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Sun Pharma Advanced Research Company Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sun Pharma Advanced Research Company Ltd is ₹196.45 and ₹474 as of 22 Jul ‘24

What is the CAGR of Sun Pharma Advanced Research Company Ltd?

Down Arrow

Sun Pharma Advanced Research Company Ltd's CAGR for 5 Years at 7.88%, 3 Years at -3.41%, 1 Year at 0.27%, 6 Month at -41.10%, 3 Month at -33.84% and 1 Month at -5.11%.

What is the shareholding pattern of Sun Pharma Advanced Research Company Ltd?

Down Arrow

The shareholding pattern of Sun Pharma Advanced Research Company Ltd is as follows:
Promoters - 65.67 %
Institutions - 2.82 %
Public - 31.51 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.